August 1, 2015
The Spectranetics Corporation announced that enrollment is completed for the ILLUMNENATE Pivotal trial, which is evaluating the use of a drug-coated angioplasty balloon to treat patients with peripheral artery disease.
The Stellarex drug-coated balloon platform (Spectranetics) is intended to restore and maintain blood flow in leg arteries above the knee in this patient population, according to a company press release. The prospective, randomized ILLUMENATE Pivotal will include 300 patients with superficial femoral or popliteal artery lesions of 3 to 14 cm. Patients were enrolled at 42 U.S. sites.